Department of Clinical Pharmacy, Na Homolce Hospital, Prague, Czech Republic.
Institute of Pharmacology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
Trials. 2020 Dec 11;21(1):1018. doi: 10.1186/s13063-020-04920-z.
Most cardiac surgery patients undergo median sternotomy during open heart surgery. Sternotomy healing is an arduous, very complex, and multifactorial process dependent on many independent factors affecting the sternum and the surrounding soft tissues. Complication rates for median sternotomy range from 0.5 to 5%; however, mortality rates from complications are very variable at 7-80%. Low calcidiol concentration below 80 nmol/L results in calcium absorptive impairment and carries a risk of bone loss, which is considered as a risk factor in the sternotomy healing process. The primary objective of this clinical trial is to compare the incidence of all postoperative sternotomy healing complications in two parallel patient groups administered cholecalciferol or placebo. The secondary objectives are focused on general patient recovery process: sternal bone healing grade at the end of the trial, length of hospitalization, number of days spent in the ICU, number of days spent on mechanical lung ventilation, and number of hospital readmissions for sternotomy complications.
This clinical trial is conducted as monocentric, randomized, double-blind, placebo-controlled, with planned enrollment of 600 patients over 4 years, approximately 300 in the placebo arm and 300 in the treatment arm. Males and females from 18 to 95 years of age who fulfill the indication criteria for undergoing cardiac surgery with median sternotomy can be included in this clinical trial, if they meet the eligibility criteria.
REINFORCE-D is the first monocentric trial dividing patients into groups based on serum calcidiol levels, and with dosing based on serum calcidiol levels. This trial may help to open up a wider range of postoperative healing issues.
EU Clinical Trials Register, EUDRA CT No: 2016-002606-39 . Registered on September 8, 2016.
大多数心脏手术患者在心脏直视手术中进行正中开胸。胸骨切开愈合是一个艰苦的、非常复杂的、多因素的过程,依赖于许多影响胸骨和周围软组织的独立因素。正中开胸术的并发症发生率为 0.5%至 5%;然而,并发症的死亡率差异很大,为 7%至 80%。血清 25-羟维生素 D 浓度低于 80nmol/L 会导致钙吸收受损,并伴有骨丢失风险,这被认为是胸骨切开愈合过程中的一个危险因素。本临床试验的主要目的是比较两组患者(给予胆钙化醇或安慰剂)术后所有胸骨切开愈合并发症的发生率。次要目标集中在患者的一般恢复过程上:试验结束时胸骨愈合分级、住院时间、入住 ICU 天数、机械通气天数和因胸骨切开并发症再次住院的次数。
该临床试验采用单中心、随机、双盲、安慰剂对照设计,计划在 4 年内招募 600 例患者,安慰剂组和治疗组各 300 例。年龄在 18 至 95 岁之间的男性和女性,符合正中开胸心脏手术指征,如果符合入选标准,均可纳入本临床试验。
REINFORCE-D 是第一个根据血清 25-羟维生素 D 水平将患者分组,并根据血清 25-羟维生素 D 水平进行剂量调整的单中心试验。该试验可能有助于解决更广泛的术后愈合问题。
欧盟临床试验注册处,EUDRA CT 编号:2016-002606-39。于 2016 年 9 月 8 日注册。